In a confidential letter to stakeholders obtained by the ABC, the TGA said the current exemptions were not designed to allow commercial-scale manufacturing driven by patient demand for weight-loss medications
Certain patients should not take GLP-1 medications
In addition to weight loss, Semaglutide has shown to reduce HbA1c levels by up to 1.8% in people with type 2 diabetes, making it an excellent choice for those looking to manage both their weight and blood sugar levels
Your prescriber will determine the appropriate maintenance dose based on your response, any side effects you experience, and your overall health profile
Hu S, Zhao R, Shen Y, Lyu B
Transcription factor modulators such as elafibranor, a PPAR ligand, have advanced to phase III trials and demonstrated efficacy in improving lipid handling and reducing hepatic steatosis